An open label, crossover study to evaluate the potential pharmacodynamic interaction between inclacumab and unfractionated heparin in healthy smokers

Trial Profile

An open label, crossover study to evaluate the potential pharmacodynamic interaction between inclacumab and unfractionated heparin in healthy smokers

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Inclacumab (Primary) ; Heparin
  • Indications Coronary artery disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 15 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top